Promising signs from Lundbeck’s depression drug
The Danish-based drug group Lundbeck has seen promising tendencies in the US sales of its depression drug Brintellix lately, but a sector analyst points out that Lundbeck’s drug is still lagging behind one of its nearest rivals.
BY BENJAMIN WERNER CHRISTENSEN
Sales of Lundbeck’s drug Brintellix to treat Major Depression Disorder (MDD) have been disappointing so far, but the Danish-based pharma group sees a reversing of the tendency when it comes to the number of prescriptions in the US, Jefferies writes in a memo in the wake of the Jefferies 2015 Global Healthcare Conference in New York.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Lundbeck CSO: It will have a huge impact
For abonnenter
Benny Bang is the man behind Brintellix
For abonnenter
R&D chief: Brintellix data are highly significant
For abonnenter
